Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report.
Charles Dela CruzScott E EvansMarcos I RestrepoNathan C DeanAntonio TorresIsabel Amara-EloriShanjana AwasthiElisabet CalerBin CaoJames D ChalmersJean ChastreTaylor S CohenAlan H CohenKristina CrothersYuan-Pu Peter DiMarie E EganCharles FeldmanSamir GautamE Scott HalsteadSusanne HeroldBarbara E JonesCarlos LunaMichael S NiedermanRaul MendezRosario MenendezJoseph P MizgerdRoomi NusratJulio RamirezYuichiro ShindoGrant WatererSamantha M YeligarRichard G WunderinkPublished in: Annals of the American Thoracic Society (2021)
Pneumonia causes a significant burden of disease worldwide. Although all populations are at risk of pneumonia, those at extremes of age and those with immunosuppressive disorders, underlying respiratory disease, and critical illness are particularly vulnerable. Although clinical practice guidelines addressing the management and treatment of pneumonia exist, few of the supporting studies focus on the crucial contributions of the host in pneumonia pathogenesis and recovery. Such essential considerations include the host risk factors that lead to susceptibility to lung infections; biomarkers reflecting the host response and the means to pursue host-directed pneumonia therapy; systemic effects of pneumonia on the host; and long-term health outcomes after pneumonia. To address these gaps, the Pneumonia Working Group of the Assembly on Pulmonary Infection and Tuberculosis led a workshop held at the American Thoracic Society meeting in May 2018 with overarching objectives to foster attention, stimulate research, and promote funding for short-term and long-term investigations into the host contributions to pneumonia. The workshop involved participants from various disciplines with expertise in lung infection, pneumonia, sepsis, immunocompromised patients, translational biology, data science, genomics, systems biology, and clinical trials. This workshop report summarizes the presentations and discussions and important recommendations for future clinical pneumonia studies. These recommendations include establishing consensus disease and outcome definitions, improved phenotyping, development of clinical study networks, standardized data and biospecimen collection and protocols, and development of innovative trial designs.
Keyphrases
- respiratory failure
- clinical trial
- community acquired pneumonia
- risk factors
- healthcare
- stem cells
- emergency department
- randomized controlled trial
- end stage renal disease
- chronic kidney disease
- mesenchymal stem cells
- acute respiratory distress syndrome
- newly diagnosed
- risk assessment
- human immunodeficiency virus
- study protocol
- machine learning
- big data
- clinical practice
- working memory
- hepatitis c virus
- cell therapy
- phase iii
- phase ii